15 news items
CytomX Therapeutics Announces Clinical Collaboration With Merck To Evaluate CX-801 In Combination With KEYTRUDA
CTMX
MRK
7 May 24
. With an improved therapeutic profile, our goal is to establish CX-801 as a cornerstone of immuno-oncology combination regimens, including
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
MRK
1 May 24
Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
MRK
MRNA
11 Apr 24
Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial.
“Given this, and in alignment
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
MRK
4 Apr 24
at transforming the way lung cancer is treated, with a goal of improving outcomes for patients affected by this deadly disease. Through nearly 200 clinical trials
1lu3p8pmvfmil4vf0bz1h8kknp34ljcm5gwk5anetoac7j yhr67
MRK
28 Mar 24
Merck is advancing research aimed at transforming the way lung cancer is treated, with a goal of improving outcomes for patients
2h3b2gpb0st wd7rxwp
MRK
26 Mar 24
treatment options continue to be needed for patients with pulmonary arterial hypertension that support important clinical goals, including increasing
rdzfo2k6xypbnwlgqvxme1rpbt1vwq95 ulbic1m4fpg9n1wp
MRK
15 Mar 24
.
Merck's focus on cancer
Our goal is to translate breakthrough science
r3zndvs5vd4w42qyfay9d7pp xkr9ga7gtk771zyw5k
MRK
13 Mar 24
of GARDASIL 9 versus the currently approved three-dose regimen. The goal of these large, randomized trials is to generate data that clearly determines whether
3nfcbmx1u ffvj9097pib8c114g3fx5a1mchfq7s
HARP
MRK
11 Mar 24
.
Merck's focus on cancer
Our goal is to translate breakthrough
hc5 80e2few7tss2rf
GILD
MRK
6 Mar 24
presented at CROI help bring us one step closer to our goal of providing a wide range of options that may help transform the HIV treatment landscape
2jvfkx6440zd4fd9a1z9rfqrx646epwvaf8pwz16lj4h2sircp3
GILD
MRK
6 Mar 24
. "These promising data presented at CROI help bring us one step closer to our goal of providing a wide range of options that may help transform the HIV treatment
bk54 na2mlsxzkdoheip6njmbgho65b1m53a
ABBV
LVTX
MRK
5 Mar 24
underscores our commitment to expanding our immunology portfolio with the ultimate goal of improving the standard of care for patients living
rjnfqtjwakx2eyiz6cqwgixpzwpq1v475rw1umvuz8rkc8 3soiwufm5orj0
ALDX
LGND
MRK
27 Feb 24
and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable
35kg41ovr 2s
MRK
23 Feb 24
Merck is advancing research aimed at transforming the way lung cancer is treated, with a goal of improving outcomes
- Prev
- 1
- Next